Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Clinical trial NCT05576896 · TERMINATED

Trial details

NCT number: NCT05576896
Sponsor: Northwestern University
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Stage IV Colorectal Cancer Positive for BRAF V600E Mutation Colorectal Cancer Colorectal Cancer Stage IV

Start date: 2022-10-10
Primary completion: 2025-10-24
Enrollment: 7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.